Search Within

Yelena Yuriy Janjigian

Formats
  1. Meeting Abstract (219)
  2. Journal Article (157)
  3. Review (11)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (403)
  2. Gastrointestinal Oncology Service (403)
  3. Solid Tumor Oncology Division (403)
  4. Center for Pancreatic Cancer Research (161)
  5. Surgery (149)
  6. Department of Pathology and Laboratory Medicine (137)

More Groups

People
  1. David Ilson (112)
  2. Geoffrey Ku (110)
  3. Laura Tang (84)
  4. David Kelsen (74)
  5. Daniela Molena (65)
  6. Steven Maron (65)

More People

Years
  1. 2025 (23)
  2. 2024 (33)
  3. 2023 (42)
  4. 2022 (37)
  5. 2021 (54)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (146)
  2. Annals of Oncology (46)
  3. Annals of Surgical Oncology (14)
  4. Annals of Surgery (13)
  5. Clinical Cancer Research (13)
  6. Oncology Research and Treatment (11)

More Publications

Publishers
  1. American Society of Clinical Oncology (152)
  2. Oxford University Press (53)
  3. American Association for Cancer Research (28)
  4. Springer (22)
  5. Elsevier Inc. (19)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (403)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Temporal modulation of antigen availability to improve antibody-tumor binding and therapeutic efficacy
    Meeting Abstract

    Pereira, P.; Mandleywala, K.; Ragupathi, A.; Mattar, M.; Monette, S.; Janjigian, Y.; Lewis, J.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: An emerging paradigm
    Review

    Nakamura, Y.; Kawazoe, A.; Lordick, F.; Janjigian, Y. Y.; Shitara, K.
    Nature Reviews Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Outcomes of neoadjuvant chemotherapy for clinical stages 2 and 3 gastric cancer patients: Analysis of timing and site of recurrence
    Journal Article

    Nakauchi, M.; Vos, E.; Tang, L. H.; Gonen, M.; Janjigian, Y. Y.; Ku, G. Y.; Ilson, D. H.; Maron, S. B.; Yoon, S. S.; Brennan, M. F.; more...
    Annals of Surgical Oncology (2021)

    Fulltext@MSK | Save
  • KEYNOTE-859: A phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma
    Journal Article

    Tabernero, J.; Bang, Y. J.; Van Cutsem, E.; Fuchs, C. S.; Janjigian, Y. Y.; Bhagia, P.; Li, K.; Adelberg, D.; Qin, S. K.
    Future Oncology (2021)

    Fulltext@MSK | Save
  • Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer
    Meeting Abstract

    Janjigian, Y.; Kawazoe, A.; Weber, P.; Luo, S.; Lonardi, S.; Kolesnik, O.; Barajas, O.; Bai, Y.; Shen, L.; Tang, Y.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection
    Meeting Abstract

    Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
    Meeting Abstract

    Tabernero, J.; Cohen, D.; Van Cutsem, E.; Janjigian, Y.; Bang, Y.; Qin, S.; Wang, A.; Hawk, N.; Shih, C.; Bhagia, P.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress
    Meeting Abstract

    Strickler, J.; Nakamura, Y.; Shitara, K.; Catenacci, D.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Lee, J.; Van Cutsem, E.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer
    Meeting Abstract

    Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S.; Hyung, W.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial
    Journal Article

    Janjigian, Y. Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. C.; more...
    Lancet (2021)

    Fulltext@MSK | Save